Clinical trials: Ophthalmic Solutions
Cataracts, Retina Surgery
Eye Drop Application Monitor, Pilot Study
The purpose of this study is to determine if an eye drop video monitoring device can accurately assess (as compared to a patient's own log or a proprietary software) the exact amount and time of eye drop delivery to a patient's…
- Conditions
- Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
- Trial name
- NCT02639845
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Alexander Eaton
Limbal Stem Cell Deficiency (LSCD)
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: Use BRM421 two times a day for at least 12 weeks Visit the clinic monthly for checkups and tests
- Trial name
- NCT07422389
- Testing
- BRM421 Ophthalmic Solution, 0.06%
- Where
- United States
- Sponsor
- BRIM Biotechnology Inc.
Eye Manifestations
Comparison of Ectoin® Containing Eye Drops and Ectoin® Containing Eye Spray With the Eye Spray Tears Again®
This study aims to gain knowledge on the duration of symptom relief of environmental disorders of the eye as might be present in allergy sufferers after allergen exposure following application of the study products.
- Trial name
- NCT04021225
- Testing
- Ectoin® Allergy Eye Drops 2%, Ectoin® Eye Spray Colloidal, Tears Again® eye spray
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Bitop AG
Allergic Conjunctivitis
Safety Study for Bepotastine Besilate Ophthalmic Solution in Normal Volunteers
Safety study for bepotastine besilate ophthalmic solution in normal volunteers
- Trial name
- NCT00586625
- Testing
- Bepreve
- Volunteers
- 861 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Dry Eye
Efficacy and Safety Study of FID 119515A
The purpose of this study was to compare the effect of FID 119515A to Blink® Tears on the integrity of tear film in adults with a history of dry eye in both eyes.
- Trial name
- NCT01833117
- Testing
- FID 119515A, Blink® Tears
- Volunteers
- 75 people
- Sponsor
- Alcon Research
Glaucoma, Ocular Hypertension
Efficacy and Safety Study of OPC-1085EL Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension
The purpose of this study is to determine the efficacy and safety of OPC-1085EL ophthalmic solution in comparison with latanoprost ophthalmic solution in subjects who are insufficiently responsive to latanoprost ophthalmic…
- Trial name
- NCT02105272
- Testing
- OPC-1085EL ophthalmic solution, Latanoprost ophthalmic solution
- Where
- Japan
- Volunteers
- 237 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Healthy Volunteers Eligible for Study; Drug Being Developed for Allergic Conjunctivitis
Safety Study of Ophthalmic Solution in Healthy, Normal Volunteers
The purpose of this study is to evaluate the safety of R89674 0.25% ophthalmic solution in healthy normal volunteers
- Trial name
- NCT00223951
- Testing
- R89674 (generic name not yet established)
- Where
- 6 sites in United States
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Vistakon Pharmaceuticals
Dry Eye
Study to Evaluate a Contact Lens Lubricating and Rewetting Drop
The objective of this study is to evaluate the product performance of investigational lubricating and rewetting drops.
- Trial name
- NCT01267656
- Testing
- Lubricating and Rewetting Drops, AMO Blink Contacts Lubricant Eye Drops
- Where
- United States
- Volunteers
- 168 people, healthy volunteers welcome
- Sponsor
- Bausch & Lomb Incorporated
Allergic Conjunctivitis
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of allergic conjunctivitis using an antigen challenge model
- Trial name
- NCT04622345
- Testing
- VSJ-110
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Vanda Pharmaceuticals
Dry Eye Syndrome
Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment
The objective of this study is to compare the safety and efficacy of BRM421 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.
- Trial name
- NCT04343287
- Testing
- BRM421
- Where
- 4 sites in United States
- Volunteers
- 220 people
- Sponsor
- BRIM Biotechnology Inc.
Dry Eye, Dry Eye Disease
PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms
Dry eye disease (DED), also called keratoconjunctivitis sicca, is a common ocular condition characterized by a loss of homeostasis of the tear film and inflammation of the ocular surface.
- Conditions
- Dry Eye, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Trial name
- NCT05825599
- Testing
- Hydroxypropyl methylcellulose eye drops
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- C.O.C. Farmaceutici S.r.l.
Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD)
Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections
This Phase 4, multicenter, randomized, double-masked clinical study evaluates the efficacy and safety of chloroprocaine hydrochloride ophthalmic gel 3% (IHEEZO) compared with routine anesthesia (topical proparacaine 0.5% combined…
- Conditions
- Diabetic Macular Edema (DME), Age-Related Macular Degeneration (AMD), Retinal Vein Occlusion, Diabetic Retinopathy (DR)
- Trial name
- Quell (NCT07456826)
- Testing
- Chloroprocaine Ophthalmic Gel 3% (IHEEZO), Proparacaine Hydrochloride Ophthalmic Solution 0.5%, Lidocaine Hydrochloride Injection 2%
- Where
- United States
- Volunteers
- 236 people
- Sponsor
- Harrow Inc
Dry Eye Syndromes
A Clinical Trial to Evaluate the Safety and Efficacy of Rreproxalap in Adults With Dry Eye Disease
A Randomized, Double-Masked, Vehicle-Controlled Crossover Clinical Trial to Assess Efficacy and Safety of 0.25% Reproxalap Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease
- Trial name
- NCT05424549
- Testing
- Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution
- Where
- Canada
- Volunteers
- 63 people
- Sponsor
- Aldeyra Therapeutics, Inc.
Primary Open Angle Glaucoma, Ocular Hypertension
A Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension -AYAME Study-
The purposes of this study are to determine the optimal concentration of DE-117 ophthalmic solution compared to the placebo ophthalmic solution and to determine if intraocular pressure reduction after 4 weeks of treatment with…
- Trial name
- NCT02623738
- Testing
- DE-117 ophthalmic solution low, DE-117 ophthalmic solution high, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 253 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Myopia
A Multi-Center Investigation of Patient Acceptability of OPTI-FREE RepleniSH® Multi-Purpose Disinfecting Solution (MPDS)
The purpose of this study was to demonstrate that current successful fulltime daily wear soft contact lens wearers using competitive multi-purpose solutions will note improved comfort when using OPTI-FREE RepleniSH®.
- Trial name
- NCT00772707
- Testing
- Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH), Contact Lenses
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Alcon Research
Open-angle Glaucoma, Ocular Hypertension
Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension
This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophthalmic Solution and once daily…
- Trial name
- NCT01068964
- Testing
- 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution, 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution
- Where
- China
- Volunteers
- 235 people
- Sponsor
- Allergan
Glaucoma, Ocular Hypertension
Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
This study will evaluate the long-term safety of bimatoprost 0.01% ophthalmic solution compared with bimatoprost 0.03% ophthalmic solution in patients with glaucoma or ocular hypertension.
- Trial name
- NCT01298700
- Testing
- bimatoprost 0.01% ophthalmic solution, bimatoprost 0.03% ophthalmic solution
- Where
- 50 sites in Belgium, Czechia and 8 more
- Volunteers
- 806 people
- Sponsor
- Allergan
Corneal Neovascularization
Clinical Evaluation of Safety and Tolerability of KDR2-2 Eye Drops in Healthy Volunteers With Pharmacokinetic Assessment
A Phase 1 randomized, double blinded, placebo-controlled, single dose escalation (SDE) and repeat dose escalation (RDE) study to evaluate safety and tolerability, and PK of KDR2-2 in healthy volunteers.
- Trial name
- NCT04620109
- Testing
- KDR2-2
- Where
- United States
- Volunteers
- 62 people, healthy volunteers welcome
- Sponsor
- Guangzhou HuiBoRui Biological Pharmaceutical Technology Co. Ltd
Persistent Corneal Epithelial Defect
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
- Trial name
- CHASE (NCT05727878)
- Testing
- KPI-012, KPI-012 Vehicle
- Where
- 46 sites in United States, Argentina and 1 more
- Volunteers
- 103 people
- Sponsor
- Combangio, Inc
Keratoconus
Placebo-controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
- Trial name
- NCT07400952
- Testing
- GLK-221 Ophthalmic Solution
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Glaukos Corporation